There is considerable controversy regarding the epigenetic control of genes implicated in type 1 diabetes and its complications. We show CTCF binding sites are sensitive to loss-of-methylation with gain-of-function in diabetes. This strengthens the evidence base against methylation changes just being an epiphenomenon with the identification of gene targets that contribute to the pathogenesis of diabetic nephropathy.